- Dec 04, 2020 Foghorn Therapeutics Announces Third Quarter 2020 Financial Results and Provides Corporate Update
- Nov 12, 2020 Foghorn Therapeutics Appoints Michael LaCascia as Chief Legal Officer
- Oct 22, 2020 Foghorn Therapeutics Announces Pricing of Initial Public Offering
- Jul 08, 2020 Foghorn® Therapeutics Announces Collaboration with Merck to Discover and Develop Novel Oncology Therapeutics Against Transcription Factor Target
- Jan 09, 2020 Foghorn® Therapeutics Appoints Scott Biller, Ph.D., to Board of Directors
